BIOCAD’s rituximab biosimilar to receive MA in India

First shipment of BIOCAD’s Acellbia to India is scheduled for September 2017.

In August 2017, BIOCAD will receive permanent market authorization in India, which represents a strategic milestone for BIOCAD’s international expansion.

Today, the Indian market for rituximab exceeds $40 million, with an annual growth of 8%. According to experts, this volume may reach $58 million in the next 5 years.

Meanwhile, India experiences low rituximab availability. Therefore, the Russian biosimilar marketed here will not only boost competition among the existing players, but will make this product available for larger numbers of patients with certain types of lymphomas and autoimmune disorders.

“We are happy to see Acellbia, our first biosimilar drug product to receive MA in India, but our efforts to register more products there will continue. In the first quarter of 2018 we plan to obtain MA for Herticad, BIOCAD's trastuzumab biosimilar which is used to treat certain types of breast cancer, and is already supplied to Syria, Sri Lanka and other countries,” says Mr. Dmitry Morozov, BIOCAD’s CEO.

The quality of Acellbia manufactured by BIOCAD, including the API, was clearly demonstrated in sizeable international clinical trials, parts of which were conducted in India. The trials were conducted in accordance with the EMA’s guidelines for the non-clinical and clinical development of biosimilar monoclonal antibodies. They demonstrated similar efficacy and safety of Acellbia in a head-to-head comparison with the original drug product by F. Hoffmann-La Roche, Ltd.

BIOCAD’s rituximab has already been authorized in seven countries, including Bolivia and Honduras, with the registration pending in 27 countries.

Since 2014, over 26,000 patients in Russia and other countries were treated with rituximab produced by BIOCAD.

The first shipment of BIOCAD’s Acellbia to India is scheduled for September 2017.